Biologics, biosimilars, intended copies and the era of competitive medicine

McCamish, 2012, The state of the art in the development of biosimilars, Clin Pharmacol Ther, 91, 405, 10.1038/clpt.2011.343 Misra, 2012, Biosimilars: current perspectives and future implications, Indian J Pharmacol, 44, 12, 10.4103/0253-7613.91859 Ahmed, 2012, Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States, Clin Ther, 34, 400, 10.1016/j.clinthera.2011.12.005 Falla, 2011, The evolving role of biologics in the treatment of chronic care, Am Health Drug Benefits, 4, S80 Tsiftsoglou, 2013, Development and regulation of biosimilars: current status and future challenges, BioDrugs, 27, 203, 10.1007/s40259-013-0020-y Leader, 2008, Protein therapeutics: a summary and pharmacological classification, Nat Rev Drug Discov, 7, 21, 10.1038/nrd2399 Tang, 2004, Pharmacokinetic aspects of biotechnology products, J Pharm Sci, 93, 2184, 10.1002/jps.20125 Fernandez, 2012, Biosimilars: company strategies to capture value from the biologics market, Pharmaceuticals, 5, 1393, 10.3390/ph5121393 Montas, 2011, Cheaper clinical trials: the real solution to the biologic industry's Gordian knot, Am J Law Med, 37, 172, 10.1177/009885881103700105 McCamish, 2011, Worldwide experience with biosimilar development, MAbs, 3, 209, 10.4161/mabs.3.2.15005 Cheraghali, 2012, Biosimilars: a unique opportunity for Iran national health sector and national pharmaceutical industry, DARU J Pharm Sci, 20, 35, 10.1186/2008-2231-20-35 Weise, 2012, Biosimilars: what clinicians should know, Blood, 120, 5111, 10.1182/blood-2012-04-425744 Ventola, 2013, Biosimilars: Part 1: Proposed regulatory criteria for FDA approval, PT, 38, 270 World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 09.04.14. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003953.pdf; 2006. Accessed 09.04.14. European Medicines Agency. Questions and Answers on biosimilar medicines (similar medicinal products). European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/12/WC500020062.pdf; EMA/837805/2011. Accessed 09.04.14. U.S. Food and Drug Administration, 2012 Knezevic, 2011, Biosimilars—global issues, national solutions, Biologicals, 39, 252, 10.1016/j.biologicals.2011.09.005 Calo-Fernández, 2012, Biosimilars: company strategies to capture value from the biologics market, Pharmaceuticals, 5, 1393, 10.3390/ph5121393 Lanthier, 2008, Economic issues with follow-on protein products, Nat Rev Drug Discov, 7, 733, 10.1038/nrd2636 Rovira, 2011 Toumi, 2012 FirstWordSM Dossier. Biosimilar drugs in Europe: threat or opportunity to innovation? FirstWordSM Dossier. <http://www.firstwordplus.com/biosimilar_drugs_in_europe_threat_or_opportunity_to_innovation.do>. Accessed 09.04.14. Haustein, 2012, Saving money in the European healthcare systems with biosimilars, GaBI J, 1, 120, 10.5639/gabij.2012.0103-4.036 Dorner, 2013, The role of biosimilars in the treatment of rheumatic diseases, Ann Rheum Dis, 72, 322, 10.1136/annrheumdis-2012-202715 Molowa, 2003, The state of biopharmaceutical manufacturing, Biotechnol Annu Rev, 9, 285, 10.1016/S1387-2656(03)09008-2 Covic, 2007, Biosimilars: recent developments, Int Urol Nephrol, 39, 261, 10.1007/s11255-006-9167-5 Berlec, 2013, Current state and recent advances in biopharmaceutical production in Escherichia coli, yeasts and mammalian cells, J Ind Microbiol Biotechnol, 40, 257, 10.1007/s10295-013-1235-0 Zhu, 2012, Mammalian cell protein expression for biopharmaceutical production, Biotechnol Adv, 30, 1158, 10.1016/j.biotechadv.2011.08.022 Kresse, 2009, Biosimilars – science, status, and strategic perspective, Eur J Pharm Biopharm, 72, 479, 10.1016/j.ejpb.2009.02.014 Revers, 2010, An introduction to biologics and biosimilars. Part II: Subsequent entry biologics: biosame or biodifferent?, Can Pharm J (Ott), 143, 184, 10.3821/1913-701X-143.4.184 Chirino, 2004, Characterizing biological products and assessing comparability following manufacturing changes, Nat Biotechnol, 22, 1383, 10.1038/nbt1030 European Medical Agencies Scientific Guidelines on Biosimilar Medicines. <http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp>. Accessed 09.04.14. European Medical Agency: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. <http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/06/WC500144124.pdf>. Accessed 09.04.14. US Food and Drug Administration. Biosimilars. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm>. Accessed 09.04.14. Biologic Medicines and Biosimilars. Biosimilar News. <http://www.biosimilarnews.com/biologic-medicines-and-biosimilars>. Accessed 09.04.14. Schellekens, 2009, Biosimilar therapeutics – what do we need to consider?, NDT Plus, 2, i27, 10.1093/ndtplus/sfn177 Declerck, 2007, Biotherapeutics in the era of biosimilars: what really matters is patient safety, Drug Saf, 30, 1087, 10.2165/00002018-200730120-00002 Scheinberg, 2012, The advent of biosimilar therapies in rheumatology – “O Brave New World”, Nat Rev Rheumatol, 8, 430, 10.1038/nrrheum.2012.84 Weise, 2011, Biosimilars – why terminology matters, Nat Biotechnol, 29, 690, 10.1038/nbt.1936